Carolina Simioni

List of Publications by Year
in descending order

28 papers	1,379 citations	430442 18 h-index	500791 28 g-index
29 all docs	29 docs citations	29 times ranked	2552 citing authors

#	Article	IF	Citations
1	Optical tissue clearing associated with 3D imaging: application in preclinical and clinical studies. Histochemistry and Cell Biology, 2022, 157, 497-511.	0.8	10
2	Two neuroendocrine G proteinâ€coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives. Journal of Cellular Physiology, 2021, 236, 2505-2518.	2.0	4
3	The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies. Frontiers in Oncology, 2021, 11, 673506.	1.3	9
4	SARS-CoV-2 nucleocapsid protein and ultrastructural modifications in small bowel of a 4-week-negative COVID-19 patient. Clinical Microbiology and Infection, 2021, 27, 936-937.	2.8	20
5	The Role of Extracellular Vesicles as Shuttles of RNA and Their Clinical Significance as Biomarkers in Hepatocellular Carcinoma. Genes, 2021, 12, 902.	1.0	4
6	MicroRNAs Patterns as Potential Tools for Diagnostic and Prognostic Follow-Up in Cancer Survivorship. Cells, 2021, 10, 2069.	1.8	9
7	Legislation to limit the environmental plastic and microplastic pollution and their influence on human exposure. Environmental Pollution, 2021, 288, 117708.	3.7	46
8	Relevance of VEGF and CD147 in different SARSâ€CoVâ€2 positive digestive tracts characterized by thrombotic damage. FASEB Journal, 2021, 35, e21969.	0.2	15
9	New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances. Hematological Oncology, 2020, 38, 22-33.	0.8	7
10	miRNAs as Influencers of Cellâ€“Cell Communication in Tumor Microenvironment. Cells, 2020, 9, 220.	1.8	53
11	Targeting mTOR in Acute Lymphoblastic Leukemia. Cells, 2019, 8, 190.	1.8	44
12	Targeting the phosphatidylinositol 3â€kinase/Akt/mechanistic target of rapamycin signaling pathway in Bâ€lineage acute lymphoblastic leukemia: An update. Journal of Cellular Physiology, 2018, 233, 6440-6454.	2.0	35
13	Phosphatidylinositol 3â€kinase inhibition potentiates glucocorticoid response in Bâ€cell acute lymphoblastic leukemia. Journal of Cellular Physiology, 2018, 233, 1796-1811.	2.0	28
14	Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging. Oncotarget, 2018, 9, 17181-17198.	0.8	303
15	Physical training interventions for children and teenagers affected by acute lymphoblastic leukemia and related treatment impairments. Oncotarget, 2018, 9, 17199-17209.	0.8	23
16	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Molecular Therapy - Nucleic Acids, 2018, 11, 485-493.	2.3	81
17	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget, 2017, 8, 23213-23227.	0.8	15
18	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 55690-55703.	0.8	14

#	Article	IF	Citations
19	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Oncotarget, 2016, 7, 79842-79853.	0.8	22
20	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget, 2015, 6, 6597-6610.	0.8	27
21	The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget, 2015, 6, 17147-17160.	0.8	30
22	Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget, 2014, 5, 10034-10047.	0.8	60
23	The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy. Oncotarget, 2013, 4, 1496-1506.	0.8	47
24	Adenosine receptors and cancer. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1400-1412.	1.4	186
25	Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors. Biochemical Pharmacology, 2010, 79, 471-477.	2.0	22
26	Regulation of Second Messenger Systems and Intracellular Pathways. , 2010, , 61-73.		5
27	A2B and A3 Adenosine Receptors Modulate Vascular Endothelial Growth Factor and Interleukin-8 Expression in Human Melanoma Cells Treated with Etoposide and Doxorubicin. Neoplasia, 2009, 11, 1064-1073.	2.3	66
28	Caffeine Inhibits Adenosine-Induced Accumulation of Hypoxia-Inducible Factor-1Î±, Vascular Endothelial Growth Factor, and Interleukin-8 Expression in Hypoxic Human Colon Cancer Cells. Molecular Pharmacology, 2007, 72, 395-406.	1.0	149